Targeting Bruton's Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Kinases are crucial drug targets involved in cell signaling, cancer, and autoimmune diseases.
• The human kinome contains over 500 kinases, posing significant selectivity challenges for drug development.
• Bruton's tyrosine kinase (BTK) is integral to B-cell receptor signaling and implicated in B-cell lymphomas and autoimmune conditions.

Purpose of the Study:

• To review the design principles of irreversible inhibitors, reversible inhibitors, and Proteolysis-targeting chimera (PROTAC) degraders targeting BTK.
• To analyze crystal structures of BTK-compound complexes to understand selective inhibition and degradation mechanisms.
• To discuss strategies for overcoming emerging BTK resistance mutations.

Main Methods:

• Literature review of BTK inhibitor and PROTAC degrader design strategies.
• Analysis of published crystal structures of BTK in complex with various inhibitors and degraders.
• Synthesis of information on BTK mutations and their impact on therapeutic strategies.

Main Results:

• Irreversible inhibitors, reversible inhibitors, and PROTAC degraders offer distinct mechanisms for targeting BTK.
• Structural insights reveal how inhibitor and degrader design influences selectivity and efficacy.
• Emerging BTK resistance mutations necessitate the development of next-generation therapeutics.

Conclusions:

• Targeting BTK is a promising therapeutic strategy for B-cell malignancies and autoimmune diseases.
• Rational drug design, informed by structural biology, is key to achieving selective BTK inhibition and degradation.
• Developing novel inhibitors and degraders is essential to overcome therapeutic resistance and improve patient outcomes.